(IN BRIEF) Novo Nordisk has announced promising headline results from the kidney outcomes trial FLOW, which compared injectable semaglutide 1.0…
(IN BRIEF) Novo Nordisk, a global healthcare company, has reported the headline findings from the SELECT cardiovascular outcomes trial. This…